Zentalis Pharmaceuticals Inc
For the period ended Mar 31, 2025. Filed May 14, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 14, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Other Information
Item 5. Other Information.
Insider Trading Arrangements and Policies.
On February 7, 2025, Mark Lackner, the Company’s Chief Scientific Officer, who ceased being an officer and an employee of the Company in April 2025, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of at least 104,221 shares of the Company’s common stock until March 29, 2026.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.